Trump sets fresh 10% global tariff — and plans to increase further

The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.

Updated Feb. 21, 2026

AI is slashing jobs across industries. Will pharma be next?

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.

Roche gets FDA decision date on closely watched breast cancer drug

The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors. 

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial. 

Grail’s multi-cancer early detection test misses study goal

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

Altesa, run by former Trump official, raises $75M for well-traveled lung drug

Led by Brett Giroir and GSK’s ex-chief medical officer, Altesa is advancing a medicine that’s changed hands multiple times and once failed a study in asthma.  

Updated Feb. 20, 2026

FDA reverses course on Moderna’s flu vaccine

In response to a query from BioPharma Dive, an HHS spokesperson said the FDA will “maintain its high standards during drug review and potential licensure stages.”

Updated Feb. 19, 2026

Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

An Alzheimer’s startup emerges with $175M in venture backing

Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S. market.

Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6

The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

Cytokinetics’ heart disease drug secured European approval. Elsewhere, Teva and Sanofi reported longer-term data from an experimental therapy targeting ulcerative colitis and Crohn’s disease.

Ocular claims a win with eye drug data even as shares sink

Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, analysts said.

Moderna shares jump as company affirms growth outlook

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Vertex’s CRISPR therapy rebounds in latest earnings

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

Ultragenyx cuts jobs as it seeks path to profit in 2027

Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer.

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

FDA removes box warnings for 6 menopausal therapies

The FDA has lifted longstanding and the most severe warnings off of hormone replacement therapies for menopausal women.

HHS elevates officials into Kennedy’s inner circle in advance of midterms

The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda.

Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor

Neurocrine and Alnylam each face investor questions about the growth potential of key franchises. Ascendis, meanwhile, saw an upbeat sales report overshadowed by the progress of an emerging rival. 

Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

Updated Feb. 12, 2026

Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.

At a House subcommittee hearing last week, lawmakers on both sides of the aisle decried the nation’s high drug costs, but Democrats argued Medicaid cuts and lapsed Affordable Care Act subsidies are worsening the problem.